Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Adagrasib

U.S. FDA Approves Lung Cancer Drug, Adagrasib

Posted on December 19, 2022
Post Views: 273

AdagrasibThe US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated locally advanced or metastatic non-small cell lung cancer in adults. This accelerated approval has been based on data received from Phase II registration enabling cohort of the KRYSTAL-1 clinical trial of 600mg oral dose taken twice a day. This Mirati drug has got approval as a second line treatment for non-small cell lung cancer characterized by a subset of KRAS mutations called KRAS G12C. Krazati is designed to bind to mutant form of KRAS G12C protein and stop it from sending the in controlled signs that are responsible for driving cancer. The FDA decision is based on the results of an open-label Phase 2 study that tested the drug in 116 patients. These patients have previously been treated with chemotherapy and a type of immunotherapy called checkpoint inhibitor.

AdagrasibKrazati is the second to hit the market that blocks a specific mutation in a protein, KRAS. Another KRAS inhibitor, Lumakras, is already available to treat patients with advanced lung cancer as a second-line therapy. Though researchers knew the protein had ties to cancer but couldn’t figure out how to get an antibody a toehold on it. In the time period of two years, FDA has granted accelerated approval to two KRAS blockers.

In this study, the main aim was to assess the number and size of tumors as well as the duration of response. The results showed 43% of objective response rate and median duration of response of 12.5 months. The common adverse reactions reported in the Krazati study were nausea, fatigue, vomiting, liver toxicity etc. One key differentiating feature of the Mirati drug is its ability to penetrative into the brain. This indication is approved under accelerated approval based on overall response rate and duration of response.

The information shared in this blog is for educational purposes only. You should consult your healthcare professional for any medical needs.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,322)
  • Lung Cancer: Symptoms and Treatment (5,655)
  • What is Non-Small-Cell Lung Cancer? (5,551)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d